The Cigna Group research snapshot
CI AI stock analysis currently reads The Cigna Group as a large, cash-generative health services and insurance platform built around Evernorth pharmacy and care services plus Cigna Healthcare employer and individual benefits. At the July 8, 2026 data cutoff, CI traded near $286.62, about 12.15x TTM EPS and 9.90x free cash flow per share using audited inputs. The CI AI stock forecast is scenario-based because pharmacy benefit manager scrutiny, medical cost trend, the July 2026 CEO transition, and health care policy can change the valuation quickly. The stock looks statistically cheaper than many quality health care franchises, but the margin of safety depends on Evernorth durability, Cigna Healthcare margin discipline, and continued free cash flow conversion.
Current price
$286.62
Market cap
$75.82 billion verified market cap
AI score
68 / 100
Rating
Cash-generative health services compounder with policy, PBM, and leadership-transition risk
Trend status
Neutral to slightly positive, trading just above key moving-average references
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Cigna combines Evernorth pharmacy, specialty, care, and benefit services with Cigna Healthcare insurance and employer benefits, creating large recurring revenue but thin reported margins. | High |
| Moat | Scale, claims data, employer relationships, provider networks, pharmacy purchasing, specialty pharmacy capabilities, and integrated benefit design create switching costs, though regulation can narrow the moat. | Medium-high |
| Management | Brian Evanko became CEO on July 1, 2026 while David Cordani moved to executive chair, signaling continuity but also creating a new execution test. | High |
| Financial trend | FY2025 revenue rose 11% to $274.9 billion, shareholders net income was about $6.0 billion, and Q1 2026 revenue rose 5% to $68.5 billion with adjusted EPS of $7.79. | High |
| Valuation | At $286.62, audited inputs show 12.15x TTM EPS, 1.81x book value, 9.90x free cash flow per share, 0.27x sales, and a 2.18% dividend yield. | High |
| Technical trend | CI is near a neutral technical zone: above the 50-day moving average near $280.68 and close to the 200-day average near $284.10, with RSI near 53.96. | Medium |
| Risk level | Key risks are PBM regulation, rebate model disruption, medical cost inflation, employer demand softness, litigation, debt, Medicare and ACA policy changes, and reputation pressure. | Medium-high |
| AI confidence | Descriptive confidence is high because company releases and third-party data align. Forecast confidence is lower because policy and sentiment are hard to model. | High data confidence |
| Investment certainty | CI has a credible value setup if earnings and cash flow hold, but it is not a low-risk compounder because the business is exposed to political and regulatory resets. | Medium |
CI AI stock forecast
The CI AI stock forecast uses the $286.62 price reference, management guidance for at least $30.35 of 2026 adjusted EPS, and a three-year scenario model. The audited model produced a bearish area near $228.50, a base area near $375.50, and a bullish area near $497.00 before dividends. The range is wide because small changes in medical costs, PBM regulation, and valuation multiples can outweigh steady revenue growth.
$470 to $510
More likely if Evernorth keeps growing, Cigna Healthcare margins remain controlled, medical cost trend is manageable, PBM rule changes are less harmful than feared, and investors reward CI with a low-teens earnings multiple.
$355 to $390
More likely if adjusted EPS compounds in the mid-single-digit range, free cash flow supports dividends and buybacks, and the market values CI near 11x forward earnings.
$215 to $240
More likely if PBM economics are reset by regulation or litigation, medical cost pressure rises, employer growth slows, debt limits repurchases, and the market applies a high-single-digit multiple.
CI AI technical analysis
CI AI technical analysis is neutral as of the July 8, 2026 cutoff. MarketWatch reported a July 7 close of $286.62, Investing.com listed a 50-day moving average near $280.68, a 200-day moving average near $284.10, and RSI near 53.96, while Barchart showed 20-day average volume near 1.68 million shares and 50-day average volume near 1.71 million shares. The setup is best treated as a range decision around $280 to $290 rather than a clean trend breakout.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $286.62 | July 7, 2026 close used for valuation and market-cap checks at the July 8, 2026 data cutoff. |
| Immediate support | $280 to $284 | This zone brackets the 50-day moving average near $280.68 and the 200-day moving average near $284.10. |
| Deeper support | $239 to $250 | The 52-week low area near $239.51 is the deeper downside reference if policy or earnings risk reprices the stock. |
| Near resistance | $295 to $305 | A move through this zone would signal improving demand before the stock retests the low-$320s 52-week high area. |
| Moving averages | 50-day near $280.68, 200-day near $284.10 | Price is slightly above both references, so the trend is constructive but not strongly extended. |
| Momentum | RSI near 53.96 | Momentum is neutral, leaving room for either a breakout or a failed range test after Q2 earnings. |
| Volume | 20-day average near 1.68 million, 50-day near 1.71 million | The July 7 volume near 1.1 million shares was below the 50-day average, so confirmation volume matters. |
| Volatility | Watch Q2 earnings, PBM headlines, medical cost trend, and CEO transition updates | Policy headlines and earnings guidance can move CI more than ordinary chart noise. |
| Invalidation | Close below $280, then below $239 for the major range | A close below $280 weakens the short-term setup. A break below the 52-week low would challenge the broader value case. |
CI AI trading strategy
The CI AI trading strategy below is a rules-based research framework, not personal advice. It links price behavior with Evernorth growth, Cigna Healthcare margins, medical cost trend, policy risk, free cash flow, debt, dividends, and buybacks.
Watch for CI to hold above the $280 to $284 moving-average zone and clear $295 to $305 while Q2 results confirm adjusted EPS guidance, stable medical costs, and steady Evernorth demand.
A failed breakout followed by a close below $280 should reduce trend confidence, especially if earnings commentary points to higher medical costs or PBM pressure.
If CI pulls back toward the $240 to $260 area without a collapse in adjusted EPS guidance, free cash flow, or balance-sheet flexibility, compare the lower price with the base-case value range.
Do not treat a lower price as attractive if regulation materially resets PBM economics, debt costs rise, or Cigna Healthcare margins deteriorate.
Track Evernorth adjusted revenue, Cigna Healthcare medical care ratio, adjusted EPS guidance, operating cash flow, free cash flow, share repurchases, dividend coverage, debt, and policy updates.
Position sizing should reflect that CI is a regulated health care services company, not a guaranteed defensive stock.
Investment research summary
Customers pay Cigna to finance, coordinate, and lower the cost of health care. Employers, health plan members, and care partners use Cigna Healthcare and Evernorth for benefits, pharmacy access, specialty care, claims management, and health services infrastructure.
The moat comes from scale, pharmacy and medical claims data, employer relationships, provider networks, specialty pharmacy operations, purchasing leverage, and integrated benefit design. The moat can narrow if regulation reduces PBM spread economics or forces new transparency rules.
The thesis fails if PBM economics are repriced, medical cost trend exceeds pricing, employer enrollment weakens, litigation costs rise, debt limits capital returns, or the CEO transition exposes execution gaps.
Brian Evanko took over as CEO on July 1, 2026 after serving as president and COO, while David Cordani became executive chair. The key test is whether continuity preserves Evernorth growth while improving public trust and policy resilience.
Cigna sits inside a long-term health care affordability problem where employers and governments need cost control. That supports demand for services, but the same affordability pressure creates political and regulatory risk for insurers and PBMs.
At $286.62, CI screens inexpensive on earnings and free cash flow, but the discount is not accidental. Margin of safety depends on whether adjusted EPS near $30, free cash flow, and buybacks remain durable under policy pressure.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CI quote reference | $286.62 close on July 7, 2026 | MarketWatch CI daily market data | July 8, 2026 |
| Market capitalization verification | $75.82 billion reported, $75.82 billion calculated from $286.62 x 264.53 million shares | Pineify financial_rigor.py and StockAnalysis statistics | July 8, 2026 |
| Shares outstanding | 264.53 million shares outstanding | StockAnalysis CI statistics | July 8, 2026 |
| FY2025 revenue and earnings | $274.9 billion revenue, $6.0 billion shareholders net income, $22.18 EPS, and $29.84 adjusted EPS | The Cigna Group FY2025 results release | July 8, 2026 |
| FY2025 revenue cross-check | $274.9 billion FY2025 revenue matched between company release and StockAnalysis | StockAnalysis CI income statement | July 8, 2026 |
| Q1 2026 revenue and earnings | $68.5 billion revenue, $1.7 billion shareholders net income, $6.26 EPS, and $7.79 adjusted EPS | The Cigna Group Q1 2026 results release | July 8, 2026 |
| Cash and debt context | $1.53 billion cash and equivalents, $30.90 billion total debt, and $23.05 billion net debt at March 31, 2026 | StockAnalysis CI balance sheet | July 8, 2026 |
| Free cash flow | $7.66 billion TTM free cash flow and $28.96 FCF per share from $8.81 billion operating cash flow less $1.15 billion capital expenditures | StockAnalysis CI cash flow and statistics | July 8, 2026 |
| Valuation ratios | 12.15x TTM PE, 1.81x book, 9.90x FCF per share, 0.27x sales, and 2.18% dividend yield from audited inputs | Pineify financial_rigor.py and StockAnalysis statistics | July 8, 2026 |
| Management transition | Brian Evanko succeeded David Cordani as CEO on July 1, 2026; Cordani became executive chair | The Cigna Group CEO transition release | July 8, 2026 |
| Technical trend data | 50-day moving average near $280.68, 200-day moving average near $284.10, RSI near 53.96, and 20-day average volume near 1.68 million shares | Investing.com CI technicals and Barchart CI technical analysis | July 8, 2026 |
This CI AI stock analysis is for informational and educational use only. It is not investment advice, a recommendation, or a guarantee of future returns. Forecast ranges are scenario estimates based on available public data as of July 8, 2026, and they can be wrong if fundamentals, health care policy, PBM regulation, medical costs, leadership execution, or investor sentiment change.
